Table 1 Comparison between patients who underwent surgery and developed postoperative complications versus those who did not (N = 339)
Variable | Level | Total Cohort N (%) | Postoperative Complications = No (N = 261, 77%) | Postoperative Complications = Yes (N = 78, 23%) | P value | ||
|---|---|---|---|---|---|---|---|
Frequency | (%) | Frequency | (%) | ||||
Age | Mean | 51.5 | 51.3 | 52 | 0.72 | ||
Median | 52 | 51 | 51.5 | ||||
SD | 14.56 | 14.6 | 14.4 | ||||
Range (Max - Min) | 69 (89 − 20) | 69 (89 − 20) | 66 (86 − 20) | ||||
Sex | Female | 201 (59.29%) | 154 | 76.62% | 47 | 23.38% | 0.84 |
Male | 138 (40.71%) | 107 | 77.54% | 31 | 22.46% | ||
Smoking Status | EX | 28 (8.26%) | 21 | 75.00% | 7 | 25.00% | 0.93 |
No | 211 (62.24%) | 162 | 76.78% | 49 | 23.22% | ||
Yes | 100 (29.5%) | 78 | 78.00% | 22 | 22.00% | ||
Preoperative Comorbidity | No | 149 (43.95%) | 119 | 79.87% | 30 | 20.13% | 0.27 |
Yes | 190 (56.05%) | 142 | 74.74% | 48 | 25.26% | ||
Number of Comorbidity | 1 | 87 (25.66%) | 64 | 73.56% | 23 | 26.44% | 0.56 |
2 | 59 (17.4%) | 47 | 79.66% | 12 | 20.34% | ||
3 | 33 (9.73%) | 24 | 72.73% | 9 | 27.27% | ||
> 3 | 11 (3.24%) | 7 | 63.64% | 4 | 36.36% | ||
Type of Comorbidity | |||||||
Hypertension | No | 227 (66.96%) | 175 | 77.09% | 52 | 22.91% | 0.9 |
Yes | 112 (33.04%) | 86 | 76.79% | 26 | 23.21% | ||
Diabetes | No | 270 (79.65%) | 209 | 77.41% | 61 | 22.59% | 0.72 |
Yes | 69 (20.35%) | 52 | 75.36% | 17 | 24.64% | ||
Cardiac Comorbidity | No | 313 (92.33%) | 242 | 77.32% | 71 | 22.68% | 0.62 |
Yes | 26 (7.67%) | 19 | 73.08% | 7 | 26.92% | ||
Pulmonary Comorbidity | No | 323 (95.28%) | 249 | 77.09% | 74 | 22.91% | 0.85 |
Yes | 16 (4.72%) | 12 | 75.00% | 4 | 25.00% | ||
Renal Comorbidity | No | 327 (96.46%) | 255 | 77.98% | 72 | 22.02% | 0.35 |
Yes | 12 (3.54%) | 6 | 50.00% | 6 | 50.00% | ||
Other | No | 225 (66.37%) | 177 | 78.67% | 48 | 21.33% | 0.3 |
Yes | 114 (33.63%) | 84 | 73.68% | 30 | 26.32% | ||
Type of cancer | Breast Cancer | 104 (30.68%) | 85 | 81.73% | 19 | 18.27% | 0.06 |
Connective tumors | 17 (5.01%) | 10 | 58.82% | 7 | 41.18% | ||
GI cancer | 66 (19.47%) | 51 | 77.27% | 15 | 22.73% | ||
Gynecology | 15 (4.42%) | 9 | 60.00% | 6 | 40.00% | ||
Head & Neck | 24 (7.08%) | 20 | 83.33% | 4 | 16.67% | ||
Hematology | 49 (14.45%) | 36 | 73.47% | 13 | 26.53% | ||
Neurosurgery | 12 (3.54%) | 6 | 50.00% | 6 | 50.00% | ||
Urology | 41 (12.09%) | 36 | 87.80% | 5 | 12.20% | ||
Other | 11 (3.24%) | 8 | 72.73% | 3 | 27.27% | ||
Metastatic Disease | No | 264 (77.88%) | 203 | 76.89% | 61 | 23.11% | 0.94 |
Yes | 75 (22.12%) | 58 | 77.33% | 17 | 22.67% | ||
Neoadjuvant Therapy | No | 166 (48.97%) | 133 | 80.12% | 33 | 19.88% | 0.37 |
Yes | 173 (51.03%) | 128 | 73.99% | 45 | 26.01% | ||
Type of Neoadjuvant Therapy | RTx | 11 (3.24%) | 7 | 63.64% | 4 | 36.36% | 0.39 |
CTx | 124 (36.58%) | 91 | 73.39% | 33 | 26.61% | ||
CRTx | 38 (11.21%) | 30 | 78.95% | 8 | 21.05% | ||
Vaccine | No | 183 (53.98%) | 143 | 78.14% | 40 | 21.86% | 0.59 |
Yes | 156 (46.02%) | 118 | 75.64% | 38 | 24.36% | ||
COVID Waves | Wave 1 | 134 (39.53%) | 111 | 42.50% | 23 | 39.50% | 0.039 |
Wave 2 | 205 (60.47%) | 150 | 57.50% | 55 | 60.50% | ||
Symptomatic | No | 152 (44.84%) | 125 | 82.24% | 27 | 17.76% | 0.039 |
Yes | 187 (55.16%) | 136 | 72.73% | 51 | 27.27% | ||
Delay Periods (Between COVID-19 and Surgery) | Less than 2 weeks | 56.0 (16.5%) | 29 | 11.1% | 27 | 34.6% | < 0.001 |
From 2 to 3 weeks | 49.0 (14.5%) | 44 | 16.9% | 5 | 6.4% | ||
More than 3 weeks | 234.0 (69.0%) | 188 | 72% | 46 | 59% | ||
ASA | 1 | 12 (3.54%) | 10 | 83.33% | 2 | 16.67% | 0.27 |
2 | 301 (88.79%) | 231 | 76.74% | 70 | 23.26% | ||
3 | 23 (6.78%) | 19 | 82.61% | 4 | 17.39% | ||
4 | 3 (0.88%) | 1 | 33.33% | 2 | 66.67% | ||
Grade of surgery | Major | 156 (46.02%) | 113 | 72.44% | 43 | 27.56% | 0.18 |
Medium | 97 (28.61%) | 78 | 80.41% | 19 | 19.59% | ||
Minor | 86 (25.37%) | 70 | 81.40% | 16 | 18.60% | ||
Length Of Stay (Days) | Mean (SD) | 3.3 (7.8) | 2.1 (3.6) | 7.3 (14.1) | < 0.0001 | ||
Range | 0–99 | 0–37 | 0–99 | ||||